AU2008268362A1 - Methods of treating RSV infections and related conditions - Google Patents

Methods of treating RSV infections and related conditions Download PDF

Info

Publication number
AU2008268362A1
AU2008268362A1 AU2008268362A AU2008268362A AU2008268362A1 AU 2008268362 A1 AU2008268362 A1 AU 2008268362A1 AU 2008268362 A AU2008268362 A AU 2008268362A AU 2008268362 A AU2008268362 A AU 2008268362A AU 2008268362 A1 AU2008268362 A1 AU 2008268362A1
Authority
AU
Australia
Prior art keywords
rsv
antibody
amino acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008268362A
Other languages
English (en)
Inventor
William Dall'acqua
Peter Kiener
Subramaniam Krishnan
Genevieve Losonksy
Bettina Richter
Joann Suzich
Herren Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2008268362A1 publication Critical patent/AU2008268362A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008268362A 2007-06-26 2008-06-25 Methods of treating RSV infections and related conditions Abandoned AU2008268362A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US94627107P 2007-06-26 2007-06-26
US60/946,271 2007-06-26
US95326007P 2007-08-01 2007-08-01
US60/953,260 2007-08-01
US5492708P 2008-05-21 2008-05-21
US61/054,927 2008-05-21
PCT/US2008/068155 WO2009003019A1 (en) 2007-06-26 2008-06-25 Methods of treating rsv infections and related conditions

Publications (1)

Publication Number Publication Date
AU2008268362A1 true AU2008268362A1 (en) 2008-12-31

Family

ID=40186020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008268362A Abandoned AU2008268362A1 (en) 2007-06-26 2008-06-25 Methods of treating RSV infections and related conditions

Country Status (8)

Country Link
US (1) US20110008329A1 (https=)
EP (1) EP2069400A4 (https=)
JP (1) JP2010531890A (https=)
KR (1) KR20100049568A (https=)
CN (1) CN101687919A (https=)
AU (1) AU2008268362A1 (https=)
CA (1) CA2688667A1 (https=)
WO (1) WO2009003019A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
PH12012502244A1 (en) * 2010-07-09 2016-09-30 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN103048450B (zh) * 2011-10-13 2015-09-30 苏州药明康德新药开发股份有限公司 高通量的rsv蛋白含量的定量检测法及其检测试剂盒
WO2013165690A1 (en) * 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
CL2015002153A1 (es) * 2015-07-31 2016-01-29 Pontificia Universidad Católica De Chile Uso de los marcadores moleculares il-3,il33 e il-12p40 para caracterizar la severidad de infecciones respiratorias por virus respiratorio sincicial y metapneumovirus humano
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
US20210347885A1 (en) * 2018-09-21 2021-11-11 The University Of North Carolina At Chapel Hill Synthetic binding agents for limiting permeation through mucus
JP7634545B2 (ja) * 2020-01-29 2025-02-21 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション ｐＨ感応性ＦＣ変異体
WO2021202463A1 (en) * 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles

Also Published As

Publication number Publication date
KR20100049568A (ko) 2010-05-12
CA2688667A1 (en) 2008-12-31
US20110008329A1 (en) 2011-01-13
CN101687919A (zh) 2010-03-31
EP2069400A4 (en) 2012-03-07
JP2010531890A (ja) 2010-09-30
EP2069400A1 (en) 2009-06-17
WO2009003019A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
US20110008329A1 (en) Methods of Treating RSV Infections And Related Conditions
US7229619B1 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) Anti-RSV antibodies
US9913894B2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20100098708A1 (en) Methods of preventing and treating rsv infections and related conditions
US6855493B2 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20120070447A1 (en) Methods of administering / dosing anti-rsv antibodies for prophylaxis and treatment
AU2006203134B2 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20120263715A1 (en) Topical Methods Of Treating RSV Infections And Related Conditions
AU2012202860B2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
HK1142914A (en) Methods of treating rsv infections and related conditions
CN101273061A (zh) 具有优化的聚集和片段化特性的抗体制剂
AU2012200987A1 (en) Methods of preventing and treating RSV infections and related conditions

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application